I don't think we can blame the old management or Takeda as they had as much to lose as anyone. However, the current owners of the product should be transparent with their plans. They would need to raise a great deal of capital to resurrect the product. Not sure they could raise much at such a tiny market cap.
They could simply sell the single dose vials and not market the multi dose vials again assuming FDA agrees. This is not a scam on shareholders but rather the risk one takes investing in the industry. Phenol is an accepted preservative and in this case something went wrong.
Weaver et al published data in the journal Toxicology and Applied Pharmacology 287 (2015) 246-252 and concluded that phenol in the formulation likely caused the anaphylactic reactions and deaths. Authors are ex FDA employees. Phenol caused release of histamine from mast cells. Purified active drug did not produce the histamine release and the reaction was dose dependent and phenol associated.